Literature DB >> 8510927

Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.

C W Miller1, A Chumakov, J Said, D L Chen, A Aslo, H P Koeffler.   

Abstract

Accumulating evidence supports the hypothesis that tumor-suppressor p53 can act as a transcriptional activator. Insertion of high-affinity p53 DNA binding sites upstream of a promoter yields a p53-responsive vector. Chimeric proteins fusing p53 and the GAL4 DNA-binding domain demonstrate the presence of a transcriptional activating domain in the N-terminus of p53. GAL4-p53 chimeras constructed using naturally occurring p53 mutations at either codon 141 (Tyr-141) or 175 (His-175) of p53 had little ability to activate the reporter gene; in contrast, mutations at either codon 248 (Trp-248) or 273 (His-273) produced greater transcriptional activities than did wild-type p53. GAL4 chimeras can be used to analyse interactions between different domains of p53 and between different p53 alleles; a DNA binding site is defined, and a simple measurement can be made of function. We had expected that coexpression of GAL4 chimeras and p53 alleles would squelch transcriptional activation downstream of GAL binding sites. Surprisingly, coexpression of either p53 (Trp-248) or (His-273) with the GALA-p53 (wild-type, His-273, Trp-248, His-175, Tyr-141) effectors conferred an increase in transcriptional activation as compared with the effector alone. Oligomerization of p53 alleles with GAL4-p53 chimeras could underlie this effect, leading to an increase in transcription-activating motifs near the promoter. To test this possibility, we constructed a GAL4-p53 C-terminal chimera with p53 residues 160-393, lacking the transcriptional activating domain but retaining regions believed to be important in p53 oligomerization. Neither GAL4-p53 (C-terminus) nor p53 expression vectors were able to transactivate G5E1B-CAT alone. Both p53 (His-273) and (Trp-248) co-expressed with GAL4-p53 (C-terminus) were able to transactivate the G5E1B-CAT reporter gene; in contrast, p53 (Tyr-141) was not able to activate transcription. p53 (Tyr-141/His-273) behaved as a dominant negative mutant and inhibited the ability of the combination of p53 (His-273) and GAL4-p53 (C-terminus) to stimulate the reporter gene. Double immunoprecipitation by sequentially using GAL4 and p53 antibodies showed that p53 (His-273) and (Tyr-141/His-273), but not p53 (Tyr-141), can efficiently oligomerize in vivo to the C-terminal region of p53. Transcriptional activating function of p53 may be modulated by oligomerization; some mutations, such as His-273 and Trp-248, participate in these functions.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8510927

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.

Authors:  Ricardo E Perez; Chad D Knights; Geetaram Sahu; Jason Catania; Vamsi K Kolukula; Daniel Stoler; Adolf Graessmann; Vasily Ogryzko; Michael Pishvaian; Christopher Albanese; Maria Laura Avantaggiati
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

Authors:  C J Di Como; C Gaiddon; C Prives
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer.

Authors:  E L Milliken; K L Lozada; E Johnson; M D Landis; D D Seachrist; I Whitten; A L M Sutton; F W Abdul-Karim; R A Keri
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

4.  Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3.

Authors:  X W Wang; K Forrester; H Yeh; M A Feitelson; J R Gu; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

5.  p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells.

Authors:  Peixin Dong; Mitsuhiro Tada; Jun-Ichi Hamada; Akihiro Nakamura; Tetsuya Moriuchi; Noriaki Sakuragi
Journal:  Clin Exp Metastasis       Date:  2007-07-18       Impact factor: 5.150

6.  Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance.

Authors:  Sanjay Popat; Richard Wort; Richard S Houlston
Journal:  BMC Cancer       Date:  2006-06-05       Impact factor: 4.430

7.  β-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer.

Authors:  Tzu-Lei Kuo; Kuang-Hung Cheng; Yan-Shen Shan; Li-Tzong Chen; Wen-Chun Hung
Journal:  Theranostics       Date:  2019-01-01       Impact factor: 11.556

8.  Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation of bax expression.

Authors:  Vishwanie S Budhram-Mahadeo; Samantha Bowen; Sonia Lee; Christina Perez-Sanchez; Elizabeth Ensor; Peter J Morris; David S Latchman
Journal:  Nucleic Acids Res       Date:  2006-12-01       Impact factor: 16.971

9.  No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines.

Authors:  K J Williams; J Heighway; J M Birch; J D Norton; D Scott
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.